We have located links that may give you full text access.
Comparative Study
Journal Article
A retrospective case series comparing the use of demineralized freeze-dried bone allograft and freeze-dried bone allograft combined with enamel matrix derivative for the treatment of advanced osseous lesions.
Journal of Periodontology 2002 August
BACKGROUND: Combined regenerative approaches have been used for treating advanced osseous lesions around teeth. The aim of combining treatments is to enhance both clinical predictability and regenerative outcome compared to a monotherapeutic approach. This case series from a private practice reports on the clinical efficacy of an enamel matrix derivative (EMD) combined with either demineralized freeze-dried bone allograft (DFDBA) or freeze-dried bone allograft (FDBA) in the treatment of advanced infrabony lesions. The advanced lesions were veneered by a rapidly formed absorbable polymer barrier of poly(DL-lactide) to enhance graft containment.
METHODS: A total of 22 consecutive patients, each contributing one infrabony lesion, are reported. After patients completed presurgical preparation, the infrabony lesions were surgically treated with a combined approach that included root surface treatment with citric acid. The two groups differed in their composite graft; one received DFDBA-EMD (n = 10) and the other received FDBA-EMD (n = 12). Patients followed a stringent postoperative protocol and were evaluated 6 months postsurgery. Clinical outcomes were assessed by changes in clinical attachment level (CAL) and probing depth (PD) from pretreatment. Surgical re-entry of several sites was possible in each group.
RESULTS: CAL at pretreatment measured 9.2 +/- 1.3 mm and 9.1 +/- 1.9 mm for DFDBA-EMD and FDBA-EMD groups, respectively, with corresponding PD of 8.4 +/- 1.6 mm and 8.9 +/- 2.0 mm for each group. At 6 months post-treatment, CALs were reduced to 4.7 +/- 1.3 mm and 3.8 +/- 1.0 mm for DFDBA-EMD and FDBA-EMD groups, respectively; with corresponding PD decreased to 3.0 +/- 0.8 mm and 3.2 +/- 1.0 mm. Relative improvements in CAL for the DFDBA-EMD and DFDBA-EMD groups were 49.1% +/- 11.0% and 57.3% +/- 9.4%, respectively (P <0.07).
CONCLUSIONS: This case series demonstrates the clinical benefits of using a combined therapeutic approach in which a biologic mediator (EMD) was combined with either DFDBA or FDBA. In this limited case series, a trend was observed towards greater improvement in clinical attachment level gain in advanced infrabony defects when EMD was combined with FDBA as compared to DFDBA. Larger prospective controlled clinical trials are needed to determine if differences exist in the relative efficacy of DFDBA versus FDBA in combination with EMD.
METHODS: A total of 22 consecutive patients, each contributing one infrabony lesion, are reported. After patients completed presurgical preparation, the infrabony lesions were surgically treated with a combined approach that included root surface treatment with citric acid. The two groups differed in their composite graft; one received DFDBA-EMD (n = 10) and the other received FDBA-EMD (n = 12). Patients followed a stringent postoperative protocol and were evaluated 6 months postsurgery. Clinical outcomes were assessed by changes in clinical attachment level (CAL) and probing depth (PD) from pretreatment. Surgical re-entry of several sites was possible in each group.
RESULTS: CAL at pretreatment measured 9.2 +/- 1.3 mm and 9.1 +/- 1.9 mm for DFDBA-EMD and FDBA-EMD groups, respectively, with corresponding PD of 8.4 +/- 1.6 mm and 8.9 +/- 2.0 mm for each group. At 6 months post-treatment, CALs were reduced to 4.7 +/- 1.3 mm and 3.8 +/- 1.0 mm for DFDBA-EMD and FDBA-EMD groups, respectively; with corresponding PD decreased to 3.0 +/- 0.8 mm and 3.2 +/- 1.0 mm. Relative improvements in CAL for the DFDBA-EMD and DFDBA-EMD groups were 49.1% +/- 11.0% and 57.3% +/- 9.4%, respectively (P <0.07).
CONCLUSIONS: This case series demonstrates the clinical benefits of using a combined therapeutic approach in which a biologic mediator (EMD) was combined with either DFDBA or FDBA. In this limited case series, a trend was observed towards greater improvement in clinical attachment level gain in advanced infrabony defects when EMD was combined with FDBA as compared to DFDBA. Larger prospective controlled clinical trials are needed to determine if differences exist in the relative efficacy of DFDBA versus FDBA in combination with EMD.
Full text links
Related Resources
Trending Papers
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app